Eli Lilly and Company (LLY) Dividend Safety Gauge & 10-Year DRIP Compounder

$1,373.70 +6.63% NYSE • Public Delayed / 60s Snapshot

Eli Lilly and Company (LLY) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (84% profit margin, 32% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.

ROARABLE B • BUY Cap $1.33T
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
RQD QUANT TACHOMETERBUY • B
025507510072
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw B+ · Rk C
Cash (19)Whales (14)SEC (12)Macro (14)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+23% Base Target
$1824 Bull$1690 Base$1473 Bear
🔴 SUNDAY NIGHT PREP • 7:00 PM ET
WHALE OPTIONS TUG-OF-WAR:45% Call Buyers ($5.4M)
55% PutsMax Pain: $1,200.00
CASH DIVIDEND + BUYBACK YIELD
0.8% Total Yield
0.49% Cash ($6.92/yr) + 0.31% Buybacks
PAYOUT SAFETY SPEEDOMETER
95/100 • FORTRESS
FREE CASH FLOW PAYOUT RATIO
17.6% of FCF
11 consecutive years of payout growth
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $41,523

Est. Year-10 Shareholder Yield: $332/yr
$11.5K
Yr 1
$13.3K
Yr 2
$15.3K
Yr 3
$17.7K
Yr 4
$20.4K
Yr 5
$23.5K
Yr 6
$27.1K
Yr 7
$31.2K
Yr 8
$36.0K
Yr 9
$41.5K
Yr 10
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher + Senior Cash-Flow & Income Strategist

Cash-Fortress Compounders: Collecting Safe Yield & Upside in LLY & Top A-Rated Leaders

  • ✓12-month Bull/Base/Bear fair-value walkthrough on LLY and its top sector rival
  • ✓The Top 5 Roarable A-Rated cash compounders with heavy executive & 13F accumulation
  • ✓Includes free daily Morning Market Weather & signal upgrade/downgrade dispatch
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
LLY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.15%▲ RESISTANCE BREAKOUT
2026-10-30O $1,286.4H $1,449.7L $1,260.3C $1,417.5VOL 15.63M
RES: $1,364.7SMA50: $1,197.1SMA200: $1,091.2
$1,491.6$1,317.9$1,144.1$970.3$796.6RES $1,364.7$1,417.52026-05-012026-06-122026-07-312026-09-112026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LLY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)
-0.53% YoY Shares

SEC XBRL FY2024 → FY2025: Net share cannibal / buyback tailwind.

Reverse-DCF Expectations Hurdle (#30)
35.5%/yr Implied 5Y Growth

vs. +45.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)
DEVELOPING · Incretin Capacity Base Reclaim

Trigger: $1452.98 • Invalidation: $1349.50

🦋 Documented & Second-Order Butterfly Connections Open Graph →
WST → LLY Confirmed Filing
West Pharmaceutical Services manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals required inside sterile single-dose and multi-dose GLP-1 auto-injector pens.
TMO → LLY Confirmed Filing
Following Novo Holdings acquisition of Catalent fill-finish sites, Eli Lilly and rival GLP-1 developers increasingly rely on Thermo Fisher Patheon sterile fill-finish lines to clear injectable pen bottlenecks.
LLY → NVO Confirmed Filing
Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.

LLY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does LLY pay a dividend and is it safe?

Eli Lilly and Company (LLY) offers a 0.49% cash dividend yield ($6.92 annualized) and 0.8% total shareholder yield including buybacks. Roarable rates its payout coverage as FORTRESS.